2,4-dihydro-1H-imidazo<2,1-c><1,4>benzoxazine | 121608-16-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: 2,4-dihydro-1H-imidazo<2,1-c><1,4>benzoxazine
• 英文别名: 2,4-dihydro-1H-imidazo[2,1-c][1,4]benzoxazine
• CAS: 121608-16-0
• 化学式: C₁₀H₁₀N₂O
• 分子量: 174.202
• InChiKey: HEWXBOVRSPXOGD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  24.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3-methylthio-2H-1,4-benzoxazine 、 2-氯乙胺盐酸盐 在 三乙胺 作用下， 以 乙醇 为溶剂， 反应 8.0h， 以67%的产率得到2,4-dihydro-1H-imidazo<2,1-c><1,4>benzoxazine
  参考文献：
  名称：

  Bartsch, Herbert; Erker, Thomas; Neubauer, Gustav, Journal of Heterocyclic Chemistry, 1989, vol. 26, p. 205 - 207

  摘要：

  DOI：

文献信息

• Fused imidazole compounds
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：US10016439B2

  公开（公告）日：2018-07-10

  The present invention provides compounds represented by formula (I), pharmaceutically acceptable salts thereof, N-oxides thereof, solvates thereof or prodrugs thereof (wherein the characters are as defined in the description). The compounds represented by formula (I) have affinity and selectivity for the gamma-aminobutyric acid A receptor subunit alpha 5 (GABAA α5) and act as GABAA α5 negative allosteric modulators (GABAA α5 NAM), so that they are useful in the prevention and/or treatment of diseases which are related to the GABAA α5 such as Alzheimer's disease.

  本发明提供了式(I)代表的化合物、其药学上可接受的盐、其N-氧化物、其溶液剂或其原药（其中特征如描述中所定义）。式（I）代表的化合物对γ-氨基丁酸A受体亚基α5（GABAA α5）具有亲和性和选择性，可作为GABAA α5负异位调节剂（GABAA α5 NAM），因此可用于预防和/或治疗与GABAA α5相关的疾病，如阿尔茨海默病。
• BARTSCH, HERBERT;ERKER, THOMAS;NEUBAUER, GUSTAV, J. HETEROCYCL. CHEM., 26,(1989) N, C. 205-207
  作者：BARTSCH, HERBERT、ERKER, THOMAS、NEUBAUER, GUSTAV

  DOI：——

  日期：——
• FUSED IMIDAZOLE COMPOUNDS
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：US20160331757A1

  公开（公告）日：2016-11-17

  The present invention provides compounds represented by formula (I), pharmaceutically acceptable salts thereof, N-oxides thereof, solvates thereof or prodrugs thereof (wherein the characters are as defined in the description). The compounds represented by formula (I) have affinity and selectivity for the gamma-aminobutyric acid A receptor subunit alpha 5 (GABA A α5) and act as GABA A α5 negative allosteric modulators (GABA A α5 NAM), so that they are useful in the prevention and/or treatment of diseases which are related to the GABA A α5 such as Alzheimer's disease.